Neuroblastoma (NB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Neuroblastoma (NB) Market Outlook
Thelansis’s “Neuroblastoma (NB) Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Neuroblastoma (NB) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Neuroblastoma
(NB) Overview
Neuroblastoma,
a malignant tumor originating from neural crest cells responsible for the
sympathetic nervous system, predominantly affects children. Its occurrence may
be sporadic or inherited in the germline, with familial cases often linked to
mutations in ALK or PHOX2B genes. Some familial cases exhibit autosomal
dominant inheritance. Additionally, common transforming mutations involve
polymorphisms in genes like BARD1, LIN28B, or FLJ22536. Genetic anomalies,
including MYCN amplification and chromosomal abnormalities, significantly
impact prognosis. Diagnosis relies on elevated urinary catecholamine
metabolites and imaging techniques like ultrasound, brain scan, or MRI. MIBG
scintigraphy and medullary analysis aid in metastasis detection. Differential diagnosis
includes nephroblastoma, while bone pain and limp may be mistaken for hip
synovitis, and peri-orbital hematomas are misinterpreted as maltreatment signs.
Treatment modalities encompass surgery, chemotherapy, radiotherapy, and
immunotherapy. However, the prognosis is notably poor for around 60% of
children over one year with metastatic disease, despite intensive treatment
efforts.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment